Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine and atropine added to standard treatment for post-dural puncture headache after caesarean section
IRCT20230920059483N1Phase 2Completed
- Sponsor
- Combined Military Hospital Kharian
- Start
- Jan 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of neostigmine and atropine in post-dural puncture headache (PDPH) (2 arms), sponsored by Combined Military Hospital Kharian. Primary endpoint: Pain intensity on visual analog scale at 72 hours. Started Jan 2023; status: completed.
02
Drugs
neostigmineatropine
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on IRCT20230920059483N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230920059483N1.